An observational study in Breast Cancer, sponsored by Libbs Farmacêutica LTDA. Active, not recruiting at 22 sites in Brazil. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.
Sponsored by Libbs Farmacêutica LTDA · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Breast Neoplasms with a site in Brazil — 52 open to participants now, 111 under way, 62 of them phase 3. Breast Neoplasms · Brazil.
Among the 351 studies in Breast Neoplasms with a site in Brazil, this one is the 25th largest by enrollment of the 40 observational ones that give a count, is one of 18 that started in 2019, is one of 40 observational ones, reaches primary completion later than 5 of the 110 other live ones, and was the 197th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →52 of the 351 studies in Breast Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:
BeOne Medicines · Sites in Brazil, United States, Australia and 13 more countries
Ages 18+
Hoffmann-La Roche · Sites in Brazil, United States, Argentina and 23 more countries
Ages 18+
Hoffmann-La Roche · Sites in Brazil, United States, Argentina and 9 more countries
Ages 18+
Eli Lilly and Company · Sites in Brazil, United States, Argentina and 16 more countries
Ages 18+
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18–65 · Women only
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 79 · Phase 3 150 · Phase 4 4
First in 1997; this study’s year is marked. 18 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 170 is close to the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 250 across the 309 interventional studies, 251 across the 40 observational. Of the 206 that completed or were terminated, 109 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 351 have an industry lead sponsor. The 10 most frequent:
Libbs Farmacêutica LTDA is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Libbs Farmacêutica LTDA has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
31 of the studies in Breast Neoplasms with a site in Brazil that are under way reach primary completion within a year, 16 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT04906395Phase 3Tolmar Inc.Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | 2027-01-30 |
| NCT06839001Phase 3Hospital do CoracaoCRYoablation for Small Tumors As Local Treatment - SIX Trial | 2027-03-01 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT04540692Phase 3Latin American Cooperative Oncology GroupEvaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer | 2027-04 |
Add all 31 to your calendar (.ics) → With an account.
Among the 351 studies in Breast Neoplasms with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Zedora registration was based on studies of women with metastatic breast cancer, but its approval includes adjuvant treatment. Thus, prospective data of drug use in localized disease are lacking, as well as are real-world safety and efficacy data, taking into consideration comorbidities and compliance difficulties.
This will be an observational study of patients receiving adjuvant Zedora at several Brazilian institutions for the purpose of describing its efficacy and safety.
An observational, multicenter, prospective, real-world study at Brazilian institutions.
Adult patients with early HER2+ breast cancer receiving adjuvant biosimilar trastuzumab (Zedora) at the participating sites after the start of the study and meeting the eligibility criteria will be invited to participate. Demographics, comorbidities, disease history, extent of exposure to biosimilar trastuzumab (Zedora), adverse events and LVEF values will be collected.
Data collection will be performed using a case report form (CRF) specifically designed for the study.
Study Treatment:
Biosimilar trastuzumab (Zedora) must be prescribed at the dosage described in the product label.
Treatment duration will be 12 months for patients starting upfront with biosimilar trastuzumab (Zedora). Patients switching at any time to biosimilar trastuzumab (Zedora) after a period of adjuvant or neoadjuvant Herceptin® use will also be included in the overall analysis and subsequently assessed in a subgroup analysis.
Sample Size:
Number of patients = 170 Given the inexistence of a specific hypothesis to be tested, the statistical analysis will be basically descriptive.
Sample size is based on the two-sided 95% confidence interval (95% CI) for the invasive disease relapse-free survival rate.
The table below shows the 95% CIs for different rates in a sample of 170 patients, with an interval size ranging between 9% and 15%.
Based on literature, a 3-year relapse-free survival between 88 and 96% is expected. According to the table above, a sample of 170 patients allows assessing this endpoint with +/- 6.0% accuracy.
Study duration:
The estimated time for patient enrollment in the study is one year and may be extended in case the sample size is not reached in this period. Biosimilar trastuzumab (Zedora) must be prescribed according to the product label and treatment duration will be up to one year. The patient will be maintained in the study for 5 years (from start of treatment), unless there is tumor recurrence (local or distant).
Adult female patients with diagnosis of early stage I to III HER2+ breast cancer confirmed by histopathology test, immunohistochemistry test and FISH, where required, according to local guidelines, and who have started biosimilar trastuzumab (Zedora) as neoadjuvant or adjuvant therapy according to the product label will be eligible for the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Efficacy endpoints: Invasive disease relapse-free survival rate
Invasive disease relapse-free survival rate
Time frame: 18 months
Efficacy endpoints: Invasive disease relapse-free survival rate
Invasive disease relapse-free survival rate
Time frame: 24 months
Efficacy endpoints: Invasive disease relapse-free survival rate
Invasive disease relapse-free survival rate
Time frame: 30 months
Efficacy endpoints: Invasive disease relapse-free survival rate
Invasive disease relapse-free survival rate
Time frame: 36 months
Efficacy endpoints: Invasive disease relapse-free survival after curative-intent surgery
Invasive disease relapse-free survival after curative-intent surgery
Time frame: 5 years
Efficacy endpoints: Overall survival after curative intent surgery
Overall survival after curative intent surgery
Time frame: 5 years
Safety endpoints: Incidence of Related Adverse Events
Incidence of Related Adverse Events
Time frame: 5 years
Safety endpoints: Total cycles per patient
Total cycles per patient
Time frame: 5 years
Safety endpoints: Incidence of dose interruption
Incidence of dose interruption
Time frame: 5 years
Plan to share: Undecided
Ran from Oct 2019 to primary completion in Dec 2022, 38 months.
Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's 38 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Libbs Farmacêutica LTDA